Abstract
C1 esterase inhibitor (C1-INH) can inhibit multiple pathways (complement, contact-kinin, coagulation, and fibrinolysis) that are all implicated in the pathophysiology of asthma. We explored the effect of human plasma-derived C1-INH on allergic lung inflammation in a house dust mite (HDM) induced asthma mouse model by daily administration of C1-INH (15 U) during the challenge phase. NaCl and HDM exposed mice had comparable plasma C1-INH levels, while bronchoalveolar lavage fluid (BALF) levels were increased in HDM exposed mice coinciding with slightly reduced activation of complement (C5a). C1-INH treatment reduced Th2 response and enhanced HDM-specific IgG1. Influx of eosinophils in BALF or lung, pulmonary damage, mucus production, procoagulant response or plasma leakage in BALF was similar in both groups. In conclusion, C1-INH dampens Th2 responses during HDM induced allergic lung inflammation.
Highlights
Asthma is a chronic airway inflammatory disease that results from an excessive immune response to common environmental allergens such as house dust mite (HDM)[1]
In the present study we determined the effect of human plasma-derived C1 esterase inhibitor (C1-INH) in a clinically relevant HDM-induced asthma mouse model
C1-INH protects against endothelial cell apoptosis,vascular permeability and mortality most likely via a direct effect on LPS that is independent of C1-INH protease inhibitor activity[21,22,23]
Summary
Asthma is a chronic airway inflammatory disease that results from an excessive immune response to common environmental allergens such as house dust mite (HDM)[1]. In 2013, the WHO estimated that worldwide 235 million people suffer from asthma and the incidence is still rising[2]. Symptoms include recurrent episodes of wheezing, coughing, chest tightness and shortness of breath in response to an allergen. Asthma cannot be cured, a combination of inhaled corticosteroids (to suppress inflammation) and a short- or long-acting β-adrenergic agonist (to open the constricting bronchial smooth muscle cells) can control the disease and improve quality of life[3]. While the majority of patients with asthma can be treated effectively with the currently available medications, adequate disease control.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
